Pulmonary hypertension

This trial tests whether riociguat, a drug that relaxes blood vessels in the lungs, can safely lower high blood pressure in the lungs of people who also have a weakened left heart chamber. Participants receive either riociguat or a placebo for 16 weeks, with doctors measuring lun…

This phase 3 trial tests whether ralinepag, an oral medication, can improve exercise capacity in people with pulmonary arterial hypertension (PAH) who have recently started PAH therapy. Participants take ralinepag or a placebo for 28 weeks, and their peak oxygen consumption durin…

This study looked at the long-term safety of an inhaled drug called treprostinil in people who have both pulmonary hypertension (high blood pressure in the lungs) and COPD. It included 41 adults who had already completed a previous study. The trial was terminated early, and the m…

This study looked at the long-term safety of the drug LTP001 in people with pulmonary arterial hypertension (PAH), a serious lung condition. It was an open-label extension for patients who had completed a previous study. However, the study was terminated early, and no one reached…

This study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …

This study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the arteries in the lungs. The goal was to see if LTP001 could improve blood flow and exercise ability. However, the trial w…

This was a very early (Phase 1) study testing a drug called HS135 in obese patients who have both pulmonary hypertension and a type of heart failure called HFpEF. The trial was terminated after enrolling only 4 people, so we have no useful information on whether HS135 is safe or …